Literature DB >> 15752375

The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria.

F W Hombhanje1, I Hwaihwanje, T Tsukahara, J Saruwatari, M Nakagawa, H Osawa, M M Paniu, N Takahashi, J K Lum, B Aumora, A Masta, M Sapuri, T Kobayakawa, A Kaneko, T Ishizaki.   

Abstract

AIMS: We assessed the disposition of oral amodiaquine (AQ) and CYP2C8 polymorphism in 20 children with falciparum malaria.
METHODS: AQ and DEAQ concentrations were determined with SPE-HPLC method. CYP2C8 genotypes were assessed by PCR-RFLP method.
RESULTS: AQ was not detectable beyond day 3 postdose. Cmax for DEAQ was reached in 3.0 days. The mean values for t1/2, MRT, and AUCtotal were 10.1 days, 15.5 days and 4512.6 microg l(-1) day, respectively. All the children were CYP2C8* homozygous.
CONCLUSION: Our data are consistent with those previously reported, and the AQ regimen seems pharmacokinetically adequate in the absence of CYP2C8 polymorphism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752375      PMCID: PMC1884785          DOI: 10.1111/j.1365-2125.2004.02257.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Long PCR amplification of Plasmodium falciparum DNA extracted from filter paper blots.

Authors:  N Sakihama; T Mitamura; A Kaneko; T Horii; K Tanabe
Journal:  Exp Parasitol       Date:  2001-01       Impact factor: 2.011

2.  Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Marianne Ridderström; Collen M Masimirembwa
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

3.  A field study on the effects of a combination of cycloguanil pamoate and amodiquine against malaria in the Rabaul area of New Guinea.

Authors:  K H Rieckmann
Journal:  Am J Trop Med Hyg       Date:  1966-11       Impact factor: 2.345

4.  Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after a single oral dose in human volunteers.

Authors:  F Laurent; S Saivin; P Chretien; J F Magnaval; F Peyron; A Sqalli; A E Tufenkji; Y Coulais; H Baba; G Campistron
Journal:  Arzneimittelforschung       Date:  1993-05

5.  The disposition of amodiaquine in man after oral administration.

Authors:  P Winstanley; G Edwards; M Orme; A Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

6.  The disposition of amodiaquine in Zambians and Nigerians with malaria.

Authors:  P A Winstanley; O Simooya; J M Kofi-Ekue; O Walker; L A Salako; G Edwards; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

7.  Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans.

Authors:  F C Churchill; L C Patchen; C C Campbell; I K Schwartz; P Nguyen-Dinh; C M Dickinson
Journal:  Life Sci       Date:  1985-01-07       Impact factor: 5.037

  7 in total
  22 in total

1.  Moving about.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

2.  Pharmacokinetic determinants of the window of selection for antimalarial drug resistance.

Authors:  K Stepniewska; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

3.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

4.  Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea.

Authors:  Rajeev K Mehlotra; Mark N Ziats; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-02-28       Impact factor: 2.953

Review 5.  Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.

Authors:  Shane A Pawluk; Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

6.  Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.

Authors:  Joel Tarning; Palang Chotsiri; Vincent Jullien; Marcus J Rijken; Martin Bergstrand; Mireille Cammas; Rose McGready; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White; Francois Nosten; Niklas Lindegardh
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

7.  Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.

Authors:  Sofia Friberg Hietala; Achuyt Bhattarai; Mwinyi Msellem; Daniel Röshammar; Abdullah S Ali; Johan Strömberg; Francis W Hombhanje; Akira Kaneko; Anders Björkman; Michael Ashton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-10       Impact factor: 2.745

8.  Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.

Authors:  George O Adjei; Kim Kristensen; Bamenla Q Goka; Lotte C G Hoegberg; Michael Alifrangis; Onike P Rodrigues; Jorgen A L Kurtzhals
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

9.  Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination.

Authors:  Muhammad Ntale; Celestino Obua; Jackson Mukonzo; Margarita Mahindi; Lars L Gustafsson; Olof Beck; Jasper W Ogwal-Okeng
Journal:  Malar J       Date:  2009-03-30       Impact factor: 2.979

10.  Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.

Authors:  Visweswaran Navaratnam; Surash Ramanathan; Mohd Suhaimi Ab Wahab; Gan Siew Hua; Sharif Mahsufi Mansor; Jean-René Kiechel; Michel Vaillant; Walter R J Taylor; Piero Olliaro
Journal:  Eur J Clin Pharmacol       Date:  2009-04-30       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.